NovaBridge Biosciences.

IMAB · NASDAQ

$1.43+$0.125 (+9.62%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $1.30

IMAB analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $8.50 (+496.5% upside)

Low: $7.07
Now: $1.43
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

IMAB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 24, 2025	Maintains	Buy	$9.00	27%

The case for and against

Updated Oct 29, 2025

Bull case

I-MAB's stock outlook is supported by its advanced drug pipeline, notably the promising development of Givastomig, which demonstrates a favorable safety profile and higher binding affinity, indicating enhanced efficacy and potential for expanded market opportunities. The anticipated Hong Kong IPO is expected to diversify the shareholder base and help align I-MAB's valuation with that of its Asia-listed peers, potentially enhancing investor interest and market perception. Moreover, the appointment of a new CFO with substantial capital markets experience bolsters I-MAB's financial strategy and enhances investor communication ahead of significant clinical milestones projected for 2026.

Bear case

I-MAB's stock experienced a decline of approximately 12% following recent announcements, indicating potential investor concerns and profit-taking activities. The company's decision to implement a hub-and-spoke model, alongside existing capacity constraints, raises questions about its operational efficiency and future growth potential. These fundamental challenges within I-MAB's strategic focus contribute to a negative outlook on its financial prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.